title: Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma.
abstract: Lenalidomide (CC-5013) is a structural derivative of thalidomide, with antiangiogenic and immunomodulatory effects. Fourteen patients with metastatic renal cell carcinoma (RCC) were enrolled on a phase 2 trial of lenalidomide administered orally at 25 mg daily for 21 days followed by a rest period of 7 days. The best response was stable disease in eight patients (57%) of the 14 evaluable patients. Toxicities included fatigue, hyperglycemia, dyspnea, and myelosuppression with decreased hemoglobin, lymphopenia, and neutropenia. Lenalidomide is tolerable, but no objective responses were observed in this clinical trial.
authors.affiliation: Genitourinary Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
authors.forename: Premal H
authors.initials: PH
authors.lastname: Patel
authors.forename: G Varuni
authors.initials: GV
authors.lastname: Kondagunta
authors.forename: Lawrence
authors.initials: L
authors.lastname: Schwartz
authors.forename: Nicole
authors.initials: N
authors.lastname: Ishill
authors.forename: Jennifer
authors.initials: J
authors.lastname: Bacik
authors.forename: John
authors.initials: J
authors.lastname: DeLuca
authors.forename: Paul
authors.initials: P
authors.lastname: Russo
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Motzer
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide